Evidence map›Paper›PMID 26069294›Full record

ArticleJournal of the American Society of Nephrology : JASN2016

Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD.

Rukshana Shroff, Helen Aitkenhead, Nikola Costa, Antonella Trivelli, Mieczyslaw Litwin, Stefano Picca, Ali Anarat, Peter Sallay, Fatih Ozaltin, Aleksandra Zurowska and 6 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. The role of nutritional vitamin D in chronic kidney disease-mineral and bone disorder in children and adults with chronic kidney disease, on dialysis, and after kidney transplantation-a European consensus statement.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  5. Article
  6. Mineral Metabolism in Children: Interrelation between Vitamin D and FGF23.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Vitamin D and Glomerulonephritis.Medicina (Kaunas, Lithuania) · 2021
    Review
  16. Klotho in Clinical Nephrology: Diagnostic and Therapeutic Implications.Clinical journal of the American Society of Nephrology : CJASN · 2020
    Review
  17. Article
  18. Vitamin D and cardiovascular disease in chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2019
    Review
  19. Article
  20. Paracrine Effects of FGF23 on the Heart.Frontiers in endocrinology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 7 countries.

Rukshana ShroffGreat Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom; Rukshana.Shroff@gosh.nhs.uk.
Helen AitkenheadGreat Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom;
Nikola CostaGreat Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom;
Antonella TrivelliG. Gaslini Institute, Genova, Italy;
Mieczyslaw LitwinThe Children's Memorial Health Institute, Warsaw, Poland;
Stefano PiccaOspedale Pediatrico Bambino Gesù, Rome, Italy;
Ali AnaratCukurova University School of Medicine, Balcali, Adana, Turkey;
Peter SallaySemmelweis University Budapest, 1st Department of Pediatrics, Budapest, Hungary;
Fatih OzaltinDepartment of Pediatric Nephrology, Hacettepe University Faculty of Medicine, Sihhiye, Ankara, Turkey;
Aleksandra ZurowskaDepartment of Paediatric and Adolescent Nephrology and Hypertension, Medical University of Gdansk, Gdansk, Poland;
Augustina JankauskieneVilnius University Paediatric Center, Vilnius, Lithuania;
Giovanni MontiniUnit of Pediatric Nephrology and Dialysis, Bologna, Italy;
Marina CharbitHopital Necker, Paris, France; and.
Franz SchaeferCenter for Pediatric & Adolescent Medicine, University of Heidelberg, Germany.
Elke WühlCenter for Pediatric & Adolescent Medicine, University of Heidelberg, Germany.
ESCAPE Trial Group
Great Ormond Street Hospital for Children NHS Foundation Trust · GBHeidelberg University · DEBambino Gesù Children's Hospital · ITChildren's Memorial Health Institute · PLCukurova University · TRGdańsk Medical University · PLHacettepe University · TRIstituto Giannina Gaslini · ITSemmelweis University · HUVilnius University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiotensin-converting enzyme inhibitors (ACEi) for renin-angiotensin-aldosterone system (RAAS) blockade are routinely used to slow CKD progression. However, vitamin D may also promote renoprotection by suppressing renin transcription through cross-talk between RAAS and vitamin D-fibroblast growth factor-23 (FGF-23)-Klotho pathways. To determine whether vitamin D levels influence proteinuria and CKD progression in children, we performed a post hoc analysis of the Effect of Strict Blood Pressure Control and ACE Inhibition on Progression of CKD in Pediatric Patients (ESCAPE) cohort. In 167 children (median eGFR 51 ml/min per 1.73 m(2)), serum 25-hydroxyvitamin D (25(OH)D), FGF-23, and Klotho levels were measured at baseline and after a median 8 months on ACEi. Children with lower 25(OH)D levels had higher urinary protein/creatinine ratios at baseline (P=0.03) and at follow-up (P=0.006). Levels of 25(OH)D and serum vitamin D-binding protein were not associated, but 25(OH)D ≤50 nmol/L associated with higher diastolic BP (P=0.004). ACEi therapy also associated with increased Klotho levels (P<0.001). The annualized loss of eGFR was inversely associated with baseline 25(OH)D level (P<0.001, r=0.32). Five-year renal survival was 75% in patients with baseline 25(OH)D ≥50 nmol/L and 50% in those with lower 25(OH)D levels (P<0.001). This renoprotective effect remained significant but attenuated with ACEi therapy (P=0.05). Renal survival increased 8.2% per 10 nmol/L increase in 25(OH)D (P=0.03), independent of eGFR; proteinuria, BP, and FGF-23 levels; and underlying renal diagnosis. In children with CKD, 25(OH)D ≥50 nmol/L was associated with greater preservation of renal function. This effect was present but attenuated with concomitant ACEi therapy.

Indexed as

AdolescentAngiotensin-Converting Enzyme InhibitorsChildDisease ProgressionFemaleFibroblast Growth Factor-23HumansMaleProteinuriaReference ValuesRenal InsufficiencyRenal Insufficiency, ChronicRetrospective StudiesVitamin D25-hydroxyvitamin DAngiotensin-Converting Enzyme InhibitorsFGF23 protein, humanFibroblast Growth Factor-23Vitamin DACE inhibitorschildrenchronic kidney diseaseglomerular filtration rateproteinuriavitamin D

Identifiers

PMID26069294
PMCPMC4696567
OpenAlexW1895075713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.